INNON and Voronoi to develop global anticancer drug… Global clinical goals for 2022

© News1

Inno.N, a global bio-health company, is developing global anticancer drugs in collaboration with Voronoi, a new drug research and development company.

‘VRN061782′, a new anticancer drug introduced by inno.N from Voronoi, is better than after the’selective RET kinase inhibitor’ series drugs. It is a principle that inhibits the activity of this gene when the RET gene among the kinases, which is a signaling substance in the body, causes a mutation or when cancer is caused by binding to another gene.

inno.N plans to develop a customized target anticancer drug that selectively targets only cancer cells with the same indicator (biomarker) in the body regardless of the location of cancer, such as lung cancer and thyroid cancer with RET gene fusion or mutation. The goal is to develop the best new anticancer drug (Best in class) in the line with differentiation such as anticancer effect, overcoming resistance, and safety.

Inno.N plans to grow the substance into one of the leading new drug pipelines to compete in the global market with the aim of entering global clinical trials in 2022.

Previously, when cancer occurred due to a problem with the RET gene, there was no suitable treatment, so’non-selective kinase treatment’ was used to attack other genes as well as the RET gene, which is the cause of the problem. However, due to the low drug response rate and side effects, anticancer drugs of the’selective RET inhibitor’ class that only inhibit RET gene activity have begun to appear.

VRN061782 showed a higher response to drug resistance than previous competitor drugs of the same class in nonclinical animal studies. In addition, cardiovascular safety was confirmed by selecting only specific genes and attacking them.

Inno.N CEO Kang Seok-hee said, “Our goal is to quickly enter the global anticancer drug market through synergy with Voronoi’s excellent new drug candidate search and research capabilities and inno.N’s new drug development capabilities.”

Voronoi CEO Kim Dae-kwon said, “Through this partnership, Voronoi has demonstrated the excellence of Voronomics®, a discovery platform that Voronoi has built.

[email protected]